NCT07848854RecruitingPhase 2
Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
Up to 30% of non-muscle-invasive bladder cancer (NMIBC) lesions may be missed by standard white-light cystoscopy, resulting in high tumor recurrence rate. This is a single-center, single-arm, phase 2 prospective study. We apply Trop2-targeted NIR-II fluorescent probe TTP-ICG with rapid incubation to ex vivo bladder specimens from patients undergoing radical cystectomy. Near-infrared fluorescence imaging is performed after short-time incubation and washing. Using histopathology as gold standard, we evaluate the sensitivity, specificity of this imaging system for identifying bladder cancer lesions, and analyze correlation between fluorescence intensity and pathological diagnosis. 30 subjects will be enrolled.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 23 Sept 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 30 Jul 2027
- Lead sponsor
- Yunnan Cancer Hospital
- Diseases
- Bladder cancer
- NCT number
- NCT07848854
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 1 Aug 2026 to the primary completion date, 30 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Suffering from other invasive malignant tumors.
- With severe comorbidities including congenital malformation, acute active inflammation, cachexia, myocardial infarction or stroke within past 6 months, severe hepatic or renal insufficiency.
Other
- Pregnant or lactating female subjects.
- Participated in another clinical trial within past 30 days.
Who the study is looking for
- Suspected or confirmed bladder tumor patients who are scheduled to undergo radical cystectomy.
- Able to provide written informed consent and comply with study protocol.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yunnan Cancer Hospital Coordinator of this site? Confirm its status | Kunming | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.